A SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method

Size: px
Start display at page:

Download "A SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method"

Transcription

1 Paper SP01 A SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method Don (Dongguang) Li, NCIC-CTG, Queen s University, Kingston, ON, Canada ABSTRACT The Health-Related Quality of Life (HRQOL) measurements have been frequently applied in clinical trials of chronic diseases (such as cancers). There are many measurement tools of HRQOL questionnaires and diverse statistical analysis methods accordingly, which make the analysis of HRQOL data rather complicated and hard to be standardized. This article provides a SAS macro application based on the standard method of HRQOL data analysis of the National Cancer Institute Clinical Trials Group (NCIN-CTG) [1] The program integrates data manipulation, statistical analyses and reports generation processes. It can calculate HRQOL domains from different measurement tools, determine visit/cycle through predefined time windows and summarize the HRQOL domains response rates. The analysis results are organized into standard statistical reports, which includes the compliance rates, baseline scores comparison, the analysis of the changes of the domain scores from baseline and the summary responses analysis results. The strategies and the kernel program codes are discussed. KEY WORDS Health-related Quality of Life (HRQOL), Statistical analysis, SAS macros INTRODUCTION As the usage of HRQOL data analysis in clinical trials becomes more and more frequent, the statistical methodologies and questionnaire tools have been developed rapidly. Some complex analysis methods were criticized for the difficulties in modeling and in results interpreting [2]. A method emphasizing the clinical meaning while avoiding complex statistical modeling is desired by clinicians and other non-statistics researchers. The National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) has been carrying out HRQOL assessments since From the plentiful experiences, NCIC-CTG has developed an approach that focuses on the clinical interpretation with a summary response (improved, stable and worsened). This approach consists of four standard steps: Calculating the compliance rates, comparing baseline scores between groups, comparing the changes of the scores from baseline, and compare the proportion of responses between the treatment groups [1]. Following this standard procedure, a SAS macro application is developed to perform the analyses. STATISTICAL ANALYSIS METHODS The baseline scores comparison uses non-parametric (the Wilcoxon Rank-sum) test. It supposes no statistically significant difference between the treatment groups; otherwise the validity of randomization will be challenged. The parametric test (comparing mean score-changes) is suggested in comparing score-changes, because it has been found that there is little practical difference between using non-parametric and parametric approaches (unpublished data). There are many approaches determining the summary response [3]. A 10% cut-off scale is recommended by NCIC- CTG standard approach, but the scale can vary according to the specific trials. If the scores exceed the cut-off scale in the defined study period, the response is classified as Improved ; while scores decline below the scale in the study period, the response is classified as Worsened. The situation that is neither improved nor worsened is classified as Stable. The Chi-square test is used to analyze the difference of the response rates between the treatment groups. PROGRAMMING STRATEGIES Although the statistical analyses methods are straightforward, there are several crucial points in the programming. First, there is usually no cycle/visit information in the HRQOL questionnaire and the cycle needs to be determined with the predefined time window. Second, the designed analyses will be conducted for all the domains. This needs looping the analyses to all domains. Third, the logic of classifying the response categories is the key part of the program. The program will detect the QOL score changes and define the response categories. Fourth, if trial specific questions/domains are used, it is hard to automatically include them into the macro application. Moreover, the domains calculation from different questionnaire tools is hard to be automated because so many forms are available and may be used.

2 To accommodate these crucial points, the following strategies are considered in the SAS programming: 1. Divide the analyses into functional modules. The modules include domain calculation, data preparation, compliance rates calculation and reporting, baseline score comparison, score-changes comparison, and response rate comparison. The cycle determination and response classification are included in the data preparation step. 2. Use a macro parameter entry to control the time window, as it might be study dependent. Specific coding may be necessary if the follow-up time is not designed in an equal period. 3. Keep the names of all the domains with the contents procedure and convert them to a macro variable array. Use do-loop to repeat the analyses on each of the domains. 4. Create the domain calculation program based on the specific questionnaire tools. So far we have programs for several most commonly used QOL tools in cancer clinical trials (EORTC30, EORTC13, SF36 and combined EORTC). More programs can be added if other alternative questionnaire tools are used and the assessment methods are provided. 5. For the extra trial specific domains, a macro string is defined in the macro parameter entries. The string lists extra domain names and will be used as an array in the data preparing step. 6. Use the logic conditions to classify the response. If the score changes reach the upper boundary it id defined as Improved ; otherwise, if the score changes reach the lower boundary it is defined as Worsened ; for the rest situations the response is defined as Stable. 7. Use standard templates to generate all the reports and save them to output files. EXAMPLES OF THE KERNEL SAS CODES The example codes for some of the key issues are shown and discussed as below. Domains calculation: QOL domains calculation is measurement tools specific. Most of the QOL questions use four or seven categories recording the patients answer on the QOL questions. Generally, the categorical scores are converted into a 100- based scale number. The calculations for functional domains and symptom domains are different. For example, in EORTC30: *** domain parameter calculation***; *** physical(functional domain)***; nm=nmiss(of q_1-q_5); if nm>2 then phys=.; else do; sum=sum(q_1,q_2,q_3,q_4,q_5); phys=100-((sum/(5-nm)-1)*100/3); *** Fatigue (symptom domain) ***; nm=nmiss(q_10,q_12,q_18); if nm>1 then fati=.; else do sum=sum(q_10,q_12,q_18); fati=((sum/(3-nm)-1)*100/3); For example if the answers for question 10, 12 and 18 are 2, 3, and 3, the converted domain score for fatigue will be Determining cycles with time window The time window is defined as a macro variable (for example, 7 days for treatment cycles). There may be different time windows for follow-up (for example, 30 days). The difference in days between the date the questionnaire is filledout and the treatment date for the cycle is calculated. If it falls within the time window, the HRQOL data belongs to the same treatment cycle/follow-up. The total number of cycles / follow-ups can be determined in the data step. The code below is the example of combining QOL and treatment data:

3 *** determine cycle no for qol ***; %do i=1 %to &cno; data qolf&i; length time $2; merge qol form3(where=(cycle=&i) in=a); by id; if a; diff=qol_dt-chem_dt; /*window adjust*/ if (-&cwd <= diff <= &cwd) then time=compbl("c&i"); output; Where macro variable &cno is the total number of cycles and &cwd is the value of time window. The new variable time is the cycle variable assigned to HRQOL data. Now All QOL records that fall into the time window find their cycles. Follow-up QOL data can be handled in the same way. data qolf&i; set qolf&i; where time="c&i"; drop cycle; % *** pool data by cycle ***; data qolfm3; set %do i=1 %to &cno; qolf&i % ; Classifying the QOL response As described above, the response is classified as Improved, Worsened and Stable. The program code firstly checks if the scores can be defined as Improved based on the score changing criteria. If so, the response is Improved even if the scores are somewhere below the lower-boundary. If it is not improved, the program checks if the response is Worsened. Finally, if neither Improved nor Worsened the response is classified as Stable. In the program code (see textbox at the right side), &varno is the number of domain variables. The macro variable &fdm is a predetermined string of all functional domain names. The program merges the cycle / followup QOL data and the baseline QOL data, and calculates the score changes. The determination of responses is different for functional and symptom domains. The response classification is performed to each domain by looping. The program gives the improved cases the value of 3 and the worsened and Stable cases 2 and 1, respectively. The largest value is kept to ensure the priority of improved cases. After this step, the responses are changed back to 1 (improved), 0 (stable) and 1 (worsened) for standard analysis. *** Define response by cut-off ***; %do i=1 %to &varno; data chng&i; merge qolfol(keep=id time allo1_cd &&q&i) bsline(keep=id s&&q&i); by id; domain=trim(left("&&q&i")); *** Do differently for F- and S-domains ***; if domain in (&fdm) then do; if &&q&i-s&&q&i>=10 then d&&q&i=3 ; else if 10>&&q&i-s&&q&i>-10 then d&&q&i=1 ; else if.<&&q&i-s&&q&i<=-10 then d&&q&i=2; else do; if &&q&i-s&&q&i>=10 then d&&q&i=2 ; else if 10>&&q&i-s&&q&i>-10 then d&&q&i=1 ; else if.<&&q&i-s&&q&i<=-10 then d&&q&i=3; proc sort; by id d&&q&i; data chng&i; set chng&i; by id d&&q&i; if last.id; /* keep the largest d&&q&i*/ if d&&q&i=3 then d&&q&i=1; else if d&&q&i=2 then d&&q&i=-1; else if d&&q&i=1 then d&&q&i=0; drop domain &&q&i s&&q&i ;

4 SELECTED REPORT EXAMPLES Compliance table: NCIC-CTG TRIAL XX00 Table #: Compliance (Received/Eligible) with QOL Assessment by Treatment Arm TREATMENT A TREATMENT B Period Eligible Received (%) Eligible Received (%) Baseline (90.8) (82.2) Cycle (85.0) (80.9) Cycle (60.1) (67.8) Cycle (52.9) (55.3) Cycle (43.8) (45.4) Cycle (35.9) (38.8) Cycle (30.7) (31.6) Cycle (0.7) 152 2(1.3) Month (39.2) (40.8) Month (20.3) (15.8) Month (9.2) 152 9(5.9) Month (5.9) 152 5(3.3) Month (6.5) 152 4(2.6) Month (2.6) 152 3(2.0) Month (1.3) 152 3(2.0) Month (0.7) 152 2(1.3) Only part of the compliance and response analyses tables are shown as examples. The reports of cross-sectional analysis by cycle/follow-up and of baseline score test are not shown here. The baseline score test displays the mean values of all QOL domains by treatment group with the test p-values. The cross- sectional comparison shows the similar results (mean domain values by treatment with test p-values) for each of the treatment cycle and follow-up. DISCUSSION HRQOL data analysis is a common practice in cancer clinical trials. Standard analysis approaches and corresponding analysis applications are required. The NCIC-CTG s standard analysis approach provides the basis for building up a robust analysis system of analyzing the HRQOL data. The NCIC-CTG s approach is simple and straightforward in statistical methodology. The data management procedures are standard. These facts make it possible to used SAS macro based programs to automate the analysis steps. The difficulties in defining cycles, determining response and repeating the analyses for all the domain variables can be concurred with the SAS programming techniques. The SAS application introduced in this article is still in its primary stage. The most important pre-requisite is that the structure and contents of the clinical datasets should be relatively standard. For example, the QOL variables should be named in the same manner (Q_1-Q_## for question number, qol_dt for the date when the HRQOL questionnaire is filled out, and so on); the dataset name and contents should also be standard (F1data for baseline, F3data for treatment, F5data for follow-up etc.). If the data structure and contents are not in the standard format, an extra step is needed to modify the datasets into the pattern that meets the requirements of the SAS application. A specific format section may be needed too, to apply the format for domain names, response levels and cycle / follow-up descriptions. There might be concerns that the NCIC-CTG standard QOL data analysis approach summarizes the response only based on one point and it may result in losing information of all the time period. Our ongoing study revealed that there is well consistency of the result of this method with the results of more complicated statistical modeling. This article is not purposed to compare statistical methodologies.

5 QOL response rates analysis NCIC-CTG TRIAL XX00 Table #: Results for QOL Response Analyses TREATMENT A TREATMENT B N (%) N (%) Domain/item Improved Stable Worsened Improved Stable Worsened P value* Physical 23(12.50) 34(18.48) 40(21.74) 27(14.67) 25(13.59) 35(19.02) Role 44(18.80) 15( 6.41) 62(26.50) 50(21.37) 19( 8.12) 44(18.80) Emotional 61(25.00) 31(12.70) 35(14.34) 66(27.05) 28(11.48) 23( 9.43) Cognitive 48(19.83) 27(11.16) 51(21.07) 51(21.07) 31(12.81) 34(14.05) Social 48(20.08) 19( 7.95) 58(24.27) 39(16.32) 30(12.55) 45(18.83) Fatigue 60(24.79) 11( 4.55) 55(22.73) 57(23.55) 18( 7.44) 41(16.94) Nausea 24( 9.92) 46(19.01) 55(22.73) 29(11.98) 27(11.16) 61(25.21) Pain 58(24.68) 26(11.06) 38(16.17) 66(28.09) 19( 8.09) 28(11.91) Dyspnea 37(15.42) 52(21.67) 36(15.00) 36(15.00) 43(17.92) 36(15.00) Sleep 57(23.85) 30(12.55) 37(15.48) 51(21.34) 37(15.48) 27(11.30) Appetite 34(14.11) 28(11.62) 63(26.14) 36(14.94) 33(13.69) 47(19.50) Constipation 39(16.12) 42(17.36) 44(18.18) 30(12.40) 48(19.83) 39(16.12) Diarrhea 10( 4.12) 91(37.45) 25(10.29) 13( 5.35) 75(30.86) 29(11.93) Financial 37(15.35) 48(19.92) 40(16.60) 33(13.69) 56(23.24) 27(11.20) Global 57(23.95) 33(13.87) 34(14.29) 47(19.75) 33(13.87) 34(14.29) Body 33(13.64) 30(12.40) 63(26.03) 41(16.94) 31(12.81) 44(18.18) (More ) CONCLUSION This article introduces the NICI-CTG standard HRQOL data analysis approach and a SAS macro oriented analysis application based on the approach. The programming strategies are discussed. For the key technical issues in data managing and analyzing, solutions with SAS programming techniques are provided. The example codes of some substantial steps are included, too. This application can be a model of automating the data analysis processes with a standard data analysis approach. REFERENCES 1. Osoba D, et al: Analysis and Reporting of Health-related Quality of Life Data from Clinical Trials: An approach of the National Cancer Institute of Canada Clinical Trials Group (unpublished). 2. Gill TM, Feinstein AR: A critical appraisal of the quality of quality-of-life measurements. J Am Med Assoc 272: , Langendijk JA, Aaronson NK, de Jong JMA, et al: Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol 19: , 2001 CONTACT INFORMATION Don (Dongguang) Li, PhD, MPH, Senior Biostatistician National Cancer Institute of Canada - Clinical Trials Group 10 Stuart Street, Queen s University, Kingston, Canada, K7L 3N Ext dli@ctg.queensu.ca

EORTC QLQ-C30 descriptive analysis with the qlqc30 command

EORTC QLQ-C30 descriptive analysis with the qlqc30 command The Stata Journal (2015) 15, Number 4, pp. 1060 1074 EORTC QLQ-C30 descriptive analysis with the qlqc30 command Caroline Bascoul-Mollevi Biostatistics Unit CTD INCa, Institut régional du Cancer de Montpellier

More information

A Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group (NCIC CTG), the European Organization for Research and

A Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group (NCIC CTG), the European Organization for Research and Randomized study of sequential cisplatintopotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life A Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group

More information

Applications of Quality of Life Outcomes in Three Recent NCIC CTG Trials: What Every New Clinician-Investigator Wants to Know

Applications of Quality of Life Outcomes in Three Recent NCIC CTG Trials: What Every New Clinician-Investigator Wants to Know Workshop # 5 Applications of Quality of Life Outcomes in Three Recent NCIC CTG Trials: What Every New Clinician-Investigator Wants to Know M. Brundage and H. Richardson Outline Nature of QOL data a brief

More information

Background. 2 5/30/2017 Company Confidential 2015 Eli Lilly and Company

Background. 2 5/30/2017 Company Confidential 2015 Eli Lilly and Company May 2017 Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: data analysis from a phase 2 study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in

More information

Intro to SPSS. Using SPSS through WebFAS

Intro to SPSS. Using SPSS through WebFAS Intro to SPSS Using SPSS through WebFAS http://www.yorku.ca/computing/students/labs/webfas/ Try it early (make sure it works from your computer) If you need help contact UIT Client Services Voice: 416-736-5800

More information

A SAS sy Study of ediary Data

A SAS sy Study of ediary Data A SAS sy Study of ediary Data ABSTRACT PharmaSUG 2017 - Paper BB14 A SAS sy Study of ediary Data Amie Bissonett, inventiv Health Clinical, Minneapolis, MN Many sponsors are using electronic diaries (ediaries)

More information

Programmatic Challenges of Dose Tapering Using SAS

Programmatic Challenges of Dose Tapering Using SAS ABSTRACT: Paper 2036-2014 Programmatic Challenges of Dose Tapering Using SAS Iuliana Barbalau, Santen Inc., Emeryville, CA Chen Shi, Santen Inc., Emeryville, CA Yang Yang, Santen Inc., Emeryville, CA In

More information

J Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION VOLUME 24 NUMBER 24 AUGUST 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National

More information

Introducing the QLU-C10D A preference-based utility measure derived from the QLQ-C30

Introducing the QLU-C10D A preference-based utility measure derived from the QLQ-C30 Introducing the QLU-C10D A preference-based utility measure derived from the QLQ-C30 Presented by Professor Madeleine King Cancer Australia Chair in Cancer Quality of Life Faculties of Science and Medicine

More information

Original Article on Palliative Radiotherapy

Original Article on Palliative Radiotherapy Original Article on Palliative Radiotherapy Quality of life in responders after palliative radiation therapy for painful bone metastases using EORTC QLQ-C30 and EORTC QLQ- BM22: results of a Brazilian

More information

Implementing Patient Report Outcome Data in Clinical Trials Analysis

Implementing Patient Report Outcome Data in Clinical Trials Analysis PharmaSUG 2017 - Paper PO04 Implementing Patient Report Outcome Data in Clinical Trials Analysis ABSTRACT Qi Wang, Amgen, Thousand Oaks, CA Over the recent decades, Health-Related Quality of Life (HRQoL)

More information

PRO ASSESSMENT IN CANCER TRIALS. Emiliano Calvo, Anita Margulies, Eric Raymond, Ian Tannock, Nadia Harbeck and Lonneke van de Poll-Franse

PRO ASSESSMENT IN CANCER TRIALS. Emiliano Calvo, Anita Margulies, Eric Raymond, Ian Tannock, Nadia Harbeck and Lonneke van de Poll-Franse PRO ASSESSMENT IN CANCER TRIALS Emiliano Calvo, Anita Margulies, Eric Raymond, Ian Tannock, Nadia Harbeck and Lonneke van de Poll-Franse DISCLOSURES Emiliano Calvo has reported no conflicts of interest

More information

UvA-DARE (Digital Academic Repository)

UvA-DARE (Digital Academic Repository) UvA-DARE (Digital Academic Repository) Modification of the EORTC QLQ-C30 (version 2.0) based on content valdity and reliability testing in large samples of patients with cancer Osoba, D.; Aaronson, N.K.;

More information

Mapping the EORTC QLQ C-30 onto the EQ-5D Instrument: The Potential to Estimate QALYs without Generic Preference Data

Mapping the EORTC QLQ C-30 onto the EQ-5D Instrument: The Potential to Estimate QALYs without Generic Preference Data Volume 12 Number 1 2009 VALUE IN HEALTH Mapping the EORTC QLQ C-30 onto the EQ-5D Instrument: The Potential to Estimate QALYs without Generic Preference Data Lynda McKenzie, MSc, Marjon van der Pol, PhD

More information

Session 6: Choosing and using HRQoL measures vs Multi-Attribute Utility Instruments QLU-C10D and EQ-5D as examples

Session 6: Choosing and using HRQoL measures vs Multi-Attribute Utility Instruments QLU-C10D and EQ-5D as examples Session 6: Choosing and using HRQoL measures vs Multi-Attribute Utility Instruments QLU-C10D and EQ-5D as examples - Madeleine King & Richard De Abreu Lourenco- Overview Learning Objectives To discuss

More information

Health Technology Assessment (HTA)

Health Technology Assessment (HTA) Health Technology Assessment (HTA) Determination of utilities for the QLQ-C30 Georg Kemmler, Eva Gamper, Bernhard Holzner Department for Psychiatry and Psychotherapy Innsbruck Medical University Austria

More information

Quality of Life in Patients with Chronic Myeloid Leukemia

Quality of Life in Patients with Chronic Myeloid Leukemia Quality of Life in Patients with Chronic Myeloid Leukemia Fabio Efficace, PhD Chairman GIMEMA WP Quality of Life Head, Health Outcomes Research Unit Italian Group for Adult Hematologic Diseases (GIMEMA)

More information

10th anniversary of 1st validated CaPspecific

10th anniversary of 1st validated CaPspecific Quality of Life after Treatment of Localised Prostate Cancer Dr Jeremy Grummet Clinical Uro-Oncology Fellow May 28, 2008 1 Why? This is important May be viewed as soft science Until we know which treatment

More information

Stata: Merge and append Topics: Merging datasets, appending datasets - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1. Terms There are several situations when working with

More information

Author's response to reviews

Author's response to reviews Author's response to reviews Title: Evaluation of Safety and Efficacy of Gefitinib ('Iressa', ZD1839) as Monotherapy in a series of Chinese Patients with Advanced Non-small-cell Lung Cancer: Experience

More information

MOBILE PATIENT-REPORTED OUTCOME (PRO) ASSESSMENT TO DRIVE ADHERENCE

MOBILE PATIENT-REPORTED OUTCOME (PRO) ASSESSMENT TO DRIVE ADHERENCE MOBILE PATIENT-REPORTED OUTCOME (PRO) ASSESSMENT TO DRIVE ADHERENCE Heather Jim, PhD Moffitt Cancer Center heather.jim@moffitt.org There are no conflicts to disclose LEARNING OBJECTIVES After reading and

More information

Annals of Oncology Advance Access published January 30, 2012

Annals of Oncology Advance Access published January 30, 2012 Advance Access published January 30, 2012 original article doi:10.1093/annonc/mdr583 Health-related quality of life in recurrent platinum-sensitive ovarian cancer results from the CALYPSO trial M. Brundage

More information

QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors

QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors Abstract C-33 Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday

More information

Health-Related Quality of Life in Brain Tumor Patients Treated with Surgery: Preliminary Result of a Single Institution

Health-Related Quality of Life in Brain Tumor Patients Treated with Surgery: Preliminary Result of a Single Institution ORIGINAL ARTICLE Brain Tumor Res Treat 2016;4(2):87-93 / pissn 2288-2405 / eissn 2288-2413 http://dx.doi.org/10.14791/btrt.2016.4.2.87 Health-Related Quality of Life in Brain Tumor Patients Treated with

More information

Allergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel

Allergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple

More information

Reliability and Validity of the Taiwan Chinese Version of the EORTC QLQ-PR25 in Assessing Quality of Life of Prostate Cancer Patients

Reliability and Validity of the Taiwan Chinese Version of the EORTC QLQ-PR25 in Assessing Quality of Life of Prostate Cancer Patients Urol Sci 2010;21(3):118 125 ORIGINAL ARTICLE Reliability and Validity of the Taiwan Chinese Version of the EORTC QLQ-PR25 in Assessing Quality of Life of Prostate Cancer Patients Wei-Chu Chie 1, Chih-Chieh

More information

Anota et al. Health and Quality of Life Outcomes 2014, 12:32

Anota et al. Health and Quality of Life Outcomes 2014, 12:32 Anota et al. Health and Quality of Life Outcomes 2014, 12:32 RESEARCH Open Access Item response theory and factor analysis as a mean to characterize occurrence of response shift in a longitudinal quality

More information

Binary Diagnostic Tests Two Independent Samples

Binary Diagnostic Tests Two Independent Samples Chapter 537 Binary Diagnostic Tests Two Independent Samples Introduction An important task in diagnostic medicine is to measure the accuracy of two diagnostic tests. This can be done by comparing summary

More information

Key words: social marketing, iron-folic acid, socioeconomic INTRODUCTION

Key words: social marketing, iron-folic acid, socioeconomic INTRODUCTION December 2005: (II)S134 S138 Positive Impact of a Weekly Iron-Folic Acid Supplement Delivered with Social Marketing to Cambodian Women: Compliance, Participation, and Hemoglobin Levels Increase with Higher

More information

Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials

Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials Paper PO05 Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials Ping Liu ABSTRACT In any phase of clinical trials, dates are very critical throughout the entire trial. However,

More information

Table of Contents. Plots. Essential Statistics for Nursing Research 1/12/2017

Table of Contents. Plots. Essential Statistics for Nursing Research 1/12/2017 Essential Statistics for Nursing Research Kristen Carlin, MPH Seattle Nursing Research Workshop January 30, 2017 Table of Contents Plots Descriptive statistics Sample size/power Correlations Hypothesis

More information

Quality of Life and Survivorship:

Quality of Life and Survivorship: Quality of Life and Survivorship: Implications for Future Ovarian Cancer Research and Care Lari Wenzel, PhD Professor of Medicine & Public Health Associate Director, Population Science and Cancer Control

More information

June 30, Marlene H. Dortch Secretary Federal Communications Commission th Street, SW Washington, DC 20554

June 30, Marlene H. Dortch Secretary Federal Communications Commission th Street, SW Washington, DC 20554 Jennie B. Chandra Senior Counsel, Federal Policy Windstream Communications, Inc. 1101 17 th Street, NW, Suite 802 Washington, DC 20036 (202) 223-7667 jennie.b.chandra@windstream.com June 30, 2011 Marlene

More information

Supporting Family Caregivers through Palliative Care

Supporting Family Caregivers through Palliative Care Supporting Family Caregivers through Palliative Care Betty Ferrell, PhD, RN, MA, FAAN, FPCN, CHPN Director and Professor Division of Nursing Research and Education City of Hope, Duarte CA Family caregivers

More information

GLOBAL HEALTH. PROMIS Pediatric Scale v1.0 Global Health 7 PROMIS Pediatric Scale v1.0 Global Health 7+2

GLOBAL HEALTH. PROMIS Pediatric Scale v1.0 Global Health 7 PROMIS Pediatric Scale v1.0 Global Health 7+2 GLOBAL HEALTH A brief guide to the PROMIS Global Health instruments: ADULT PEDIATRIC PARENT PROXY PROMIS Scale v1.0/1.1 Global Health* PROMIS Scale v1.2 Global Health PROMIS Scale v1.2 Global Mental 2a

More information

What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012

What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012 What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012 Disclaimer The opinions expressed in this presentation and on the following slides are solely

More information

The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative

The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative JNCI J Natl Cancer Inst (2016) 108(5): djv391 doi:10.1093/jnci/djv391 First published online December 28, 2015 Review The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of

More information

LARYNGEAL CANCER IN EGYPT: QUALITY OF LIFE MEASUREMENT WITH DIFFERENT TREATMENT MODALITIES

LARYNGEAL CANCER IN EGYPT: QUALITY OF LIFE MEASUREMENT WITH DIFFERENT TREATMENT MODALITIES ORIGINAL ARTICLE LARYNGEAL CANCER IN EGYPT: QUALITY OF LIFE MEASUREMENT WITH DIFFERENT TREATMENT MODALITIES Ossama A. Hamid, MD, 1 Lobna M. El Fiky, MD, 1 Medani M. Medani, MD, 1 Ayman AbdelHady, MBBCh,

More information

Impact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis?

Impact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis? Impact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis? Thomas André Ankill Kämpe 30.05.2016 MED 3950,-5 year thesis Profesjonsstudiet i medisin

More information

BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS

BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS Nan Shao, Ph.D. Director, Biostatistics Premier Research Group, Limited and Mark Jaros, Ph.D. Senior

More information

Pharmaceutical Applications

Pharmaceutical Applications Creating an Input Dataset to Produce Incidence and Exposure Adjusted Special Interest AE's Pushpa Saranadasa, Merck & Co., Inc. Abstract Most adverse event (AE) summary tables display the number of patients

More information

Buy full version here - for $7.00

Buy full version here - for $7.00 This is a Sample version of the Irritable Bowel Syndrome Quality Of Life (IBS-QOL) - The full version of Irritable Bowel Syndrome - Quality Of Life (IBS-QOL) comes without sample watermark.. The full complete

More information

Improved Transparency in Key Operational Decisions in Real World Evidence

Improved Transparency in Key Operational Decisions in Real World Evidence PharmaSUG 2018 - Paper RW-06 Improved Transparency in Key Operational Decisions in Real World Evidence Rebecca Levin, Irene Cosmatos, Jamie Reifsnyder United BioSource Corp. ABSTRACT The joint International

More information

Cost-effectiveness of osimertinib (Tagrisso )

Cost-effectiveness of osimertinib (Tagrisso ) Cost-effectiveness of osimertinib (Tagrisso ) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung

More information

Review of Veterinary Epidemiologic Research by Dohoo, Martin, and Stryhn

Review of Veterinary Epidemiologic Research by Dohoo, Martin, and Stryhn The Stata Journal (2004) 4, Number 1, pp. 89 92 Review of Veterinary Epidemiologic Research by Dohoo, Martin, and Stryhn Laurent Audigé AO Foundation laurent.audige@aofoundation.org Abstract. The new book

More information

Multidimensional fatigue and its correlates in hospitalized advanced cancer patients

Multidimensional fatigue and its correlates in hospitalized advanced cancer patients Chapter 5 Multidimensional fatigue and its correlates in hospitalized advanced cancer patients Michael Echtelda,b Saskia Teunissenc Jan Passchierb Susanne Claessena, Ronald de Wita Karin van der Rijta

More information

Math Workshop On-Line Tutorial Judi Manola Paul Catalano. Slide 1. Slide 3

Math Workshop On-Line Tutorial Judi Manola Paul Catalano. Slide 1. Slide 3 Kinds of Numbers and Data First we re going to think about the kinds of numbers you will use in the problems you will encounter in your studies. Then we will expand a bit and think about kinds of data.

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly

More information

This was a multinational, multicenter study conducted at 14 sites in both the United States (US) and Europe (EU).

This was a multinational, multicenter study conducted at 14 sites in both the United States (US) and Europe (EU). These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. NAME OF SPONSOR/COMPANY: Genzyme Corporation,

More information

Introduction to SPSS S0

Introduction to SPSS S0 Basic medical statistics for clinical and experimental research Introduction to SPSS S0 Katarzyna Jóźwiak k.jozwiak@nki.nl November 10, 2017 1/55 Introduction SPSS = Statistical Package for the Social

More information

CHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials

CHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials CHL 5225 H Advanced Statistical Methods for Clinical Trials Two sources for course material 1. Electronic blackboard required readings 2. www.andywillan.com/chl5225h code of conduct course outline schedule

More information

25. Two-way ANOVA. 25. Two-way ANOVA 371

25. Two-way ANOVA. 25. Two-way ANOVA 371 25. Two-way ANOVA The Analysis of Variance seeks to identify sources of variability in data with when the data is partitioned into differentiated groups. In the prior section, we considered two sources

More information

Version No. 7 Date: July Please send comments or suggestions on this glossary to

Version No. 7 Date: July Please send comments or suggestions on this glossary to Impact Evaluation Glossary Version No. 7 Date: July 2012 Please send comments or suggestions on this glossary to 3ie@3ieimpact.org. Recommended citation: 3ie (2012) 3ie impact evaluation glossary. International

More information

Nutritional Counselling, cancer Outcome and Quality of Life!

Nutritional Counselling, cancer Outcome and Quality of Life! Nutritional Counselling, cancer Outcome and Quality of Life! Paula Ravasco p.ravasco@fm.ul.pt Unit of Nutrition and Metabolism, Institute of Molecular Medicine Faculty of Medicine of the University of

More information

Math Workshop On-Line Tutorial Judi Manola Paul Catalano

Math Workshop On-Line Tutorial Judi Manola Paul Catalano Math Workshop On-Line Tutorial Judi Manola Paul Catalano 1 Session 1 Kinds of Numbers and Data, Fractions, Negative Numbers, Rounding, Averaging, Properties of Real Numbers, Exponents and Square Roots,

More information

Health-related quality of life a prospective cohort study in phase I oncology trial participants 1

Health-related quality of life a prospective cohort study in phase I oncology trial participants 1 Health-related quality of life a prospective cohort study in phase I oncology trial participants 1 28 August 2018 Diane (A.J.) van der Biessen 2, Wendy H. Oldenmenger, Peer G. van der Helm, Dennis Klein,

More information

List of Figures. List of Tables. Preface to the Second Edition. Preface to the First Edition

List of Figures. List of Tables. Preface to the Second Edition. Preface to the First Edition List of Figures List of Tables Preface to the Second Edition Preface to the First Edition xv xxv xxix xxxi 1 What Is R? 1 1.1 Introduction to R................................ 1 1.2 Downloading and Installing

More information

Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study

Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study Original Article Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study Vithusha Ganesh, Stephanie Chan, Liying Zhang, Leah Drost, Carlo

More information

Quality of Life After Adjuvant Intra-Arterial Chemotherapy and Radiotherapy Versus Surgery Alone in Resectable Pancreatic and Periampullary Cancer

Quality of Life After Adjuvant Intra-Arterial Chemotherapy and Radiotherapy Versus Surgery Alone in Resectable Pancreatic and Periampullary Cancer Quality of Life After Adjuvant Intra-Arterial Chemotherapy and Radiotherapy Versus Surgery Alone in Resectable Pancreatic and Periampullary Cancer A Prospective Randomized Controlled Study Marjolein J.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Binary Diagnostic Tests Paired Samples

Binary Diagnostic Tests Paired Samples Chapter 536 Binary Diagnostic Tests Paired Samples Introduction An important task in diagnostic medicine is to measure the accuracy of two diagnostic tests. This can be done by comparing summary measures

More information

In Woong Han 1, O Choel Kwon 1, Min Gu Oh 1, Yoo Shin Choi 2, and Seung Eun Lee 2. Departments of Surgery, Dongguk University College of Medicine 2

In Woong Han 1, O Choel Kwon 1, Min Gu Oh 1, Yoo Shin Choi 2, and Seung Eun Lee 2. Departments of Surgery, Dongguk University College of Medicine 2 Effect of Rowachol on Prevention of Postcholecystectomy Syndrome after Laparoscopic Cholecystectomy - Prospective multicenter Randomized controlled trial- In Woong Han 1, O Choel Kwon 1, Min Gu Oh 1, Yoo

More information

ClinicalTrials.gov a programmer s perspective

ClinicalTrials.gov a programmer s perspective PhUSE 2009, Basel ClinicalTrials.gov a programmer s perspective Ralf Minkenberg Boehringer Ingelheim Pharma GmbH & Co. KG PhUSE 2009, Basel 1 Agenda ClinicalTrials.gov Basic Results disclosure Initial

More information

MEET MARY KISQALI PATIENT PROFILES

MEET MARY KISQALI PATIENT PROFILES KISQALI PATIENT PROFILES MEET MARY Mary was recently diagnosed with HR+/HER2- metastatic breast cancer Review the data from the MONALEESA-2 trial to see how patients like Mary responded The patient profile

More information

Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer

Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy

More information

Section 6: Analysing Relationships Between Variables

Section 6: Analysing Relationships Between Variables 6. 1 Analysing Relationships Between Variables Section 6: Analysing Relationships Between Variables Choosing a Technique The Crosstabs Procedure The Chi Square Test The Means Procedure The Correlations

More information

Chronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham

Chronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham Chronic Kidney Disease Paul Cockwell Queen Elizabeth Hospital Birmingham Paradigms for chronic disease 1. Acute and chronic disease is closely linked 2. Stratify risk and tailor interventions around failure

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle   holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/46692 holds various files of this Leiden University dissertation Author: Zanten, Henriëtte van Title: Oxygen titration and compliance with targeting oxygen

More information

Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D

Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D HEALTH-RELATED QUALITY OF LIFE Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D Matthijs M. Versteegh, MA, Annemieke Leunis, MSc, Jolanda J. Luime, PhD, Mike Boggild, MD, MRCP, Carin A. Uyl-de Groot, PhD, Elly

More information

Feasibility Evaluation of a Novel Ultrasonic Method for Prosthetic Control ECE-492/3 Senior Design Project Fall 2011

Feasibility Evaluation of a Novel Ultrasonic Method for Prosthetic Control ECE-492/3 Senior Design Project Fall 2011 Feasibility Evaluation of a Novel Ultrasonic Method for Prosthetic Control ECE-492/3 Senior Design Project Fall 2011 Electrical and Computer Engineering Department Volgenau School of Engineering George

More information

RESPONSE (NCT )

RESPONSE (NCT ) Changes in Quality of Life and Disease-Related Symptoms in Patients With Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results Abstract #709 Mesa R, Verstovsek S, Kiladjian

More information

Differences between Cancer Patients Symptoms Reported by Themselves and in Medical Records

Differences between Cancer Patients Symptoms Reported by Themselves and in Medical Records Differences between Cancer Patients Symptoms Reported by Themselves and in Medical Records Ana Joaquim 1, Sandra Custódio 1, Alexandra Oliveira 2,3,4 & Francisco Luís Pimentel 2,3,4,5 1 Oncology Department,

More information

C++ in the Lab. Lab Manual to Accompany C++ How to Program, Fourth Edition. H. M. Deitel Deitel & Associates, Inc.

C++ in the Lab. Lab Manual to Accompany C++ How to Program, Fourth Edition. H. M. Deitel Deitel & Associates, Inc. C++ in the Lab Lab Manual to Accompany C++ How to Program, Fourth Edition H. M. Deitel Deitel & Associates, Inc. P. J. Deitel Deitel & Associates, Inc. T. R. Nieto Deitel & Associates, Inc. Prentice Hall

More information

Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer

Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer Ran et al. Radiation Oncology (2017) 12:195 DOI 10.1186/s13014-017-0909-6 RESEARCH Open Access Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung

More information

The Relationship Between Cancer-Related Fatigue and Patient Satisfaction with Quality of Life in Cancer

The Relationship Between Cancer-Related Fatigue and Patient Satisfaction with Quality of Life in Cancer 40 Journal of Pain and Symptom Management Vol. 34 No. 1 July 2007 Original Article The Relationship Between Cancer-Related Fatigue and Patient Satisfaction with Quality of Life in Cancer Digant Gupta,

More information

Reliability and validity of the Cancer Therapy Satisfaction Questionnaire in lung cancer

Reliability and validity of the Cancer Therapy Satisfaction Questionnaire in lung cancer Qual Life Res (2016) 25:71 80 DOI 10.1007/s11136-015-1062-z Reliability and validity of the Cancer Therapy Satisfaction Questionnaire in lung cancer K. Cheung 1,4 M. de Mol 2,3 S. Visser 1,2,3 B. L. Den

More information

Functional Status and Health-Related Quality of Life in Patients with Primary Intracranial Tumour

Functional Status and Health-Related Quality of Life in Patients with Primary Intracranial Tumour ORIGINAL ARTICLE Functional Status and Health-Related Quality of Life in Patients with Primary Intracranial Tumour Ooi Ai Lee, MRehab Med, Mazlina Mazlan, MBBS, MRehabMed Department of Rehabilitation Medicine,

More information

Dr. Atsuo Yanagisawa President Japanese College of Intravenous Therapy International Society for Orthomolecular Medicine

Dr. Atsuo Yanagisawa President Japanese College of Intravenous Therapy International Society for Orthomolecular Medicine Intravenous Vitamin C Therapy In Japan Dr. Atsuo Yanagisawa President Japanese College of Intravenous Therapy International Society for Orthomolecular Medicine 1 Dr. Atsuo Yanagisawa, MD, PhD Director

More information

IMPACT OF PATIENT COUNSELING BY CLINICAL PHARMACIST ON QUALITY OF LIFE IN CANCER PATIENTS

IMPACT OF PATIENT COUNSELING BY CLINICAL PHARMACIST ON QUALITY OF LIFE IN CANCER PATIENTS WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Chowdary et al. SJIF Impact Factor 6.647 Volume 6, Issue 4, 1093-1099 Research Article ISSN 2278 4357 IMPACT OF PATIENT COUNSELING BY CLINICAL PHARMACIST

More information

How to select an age-friendly fitness facility

How to select an age-friendly fitness facility How to select an age-friendly fitness facility How to select an age-friendly fitness facility The International Council on Active Aging (ICAA), the world s largest senior fitness association, has created

More information

PROSPERO International prospective register of systematic reviews

PROSPERO International prospective register of systematic reviews PROSPERO International prospective register of systematic reviews The effect of probiotics on functional constipation: a systematic review of randomised controlled trials EIRINI DIMIDI, STEPHANOS CHRISTODOULIDES,

More information

Preoperative Quality of Life in Patients with Gastric Cancer

Preoperative Quality of Life in Patients with Gastric Cancer pissn : 2093-582X, eissn : 2093-5641 J Gastric Cancer 2015;15(2):121-126 http://dx.doi.org/10.5230/jgc.2015.15.2.121 Original Article Preoperative Quality of Life in Patients with Gastric Cancer Hyoam

More information

Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients

Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients Palliative and Supportive Care (2009), 7, 289 297. Copyright # Cambridge University Press, 2009 1478-9515/09 $20.00 doi:10.1017/s1478951509990216 Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors

More information

Author Block M. Fisch, J. W. Lee, J. Manola, L. Wagner, V. Chang, P. Gilman, K. Lear, L. Baez, C. Cleeland University of Texas M.D. Anderson Cancer Ce

Author Block M. Fisch, J. W. Lee, J. Manola, L. Wagner, V. Chang, P. Gilman, K. Lear, L. Baez, C. Cleeland University of Texas M.D. Anderson Cancer Ce Survey of disease and treatment-related t t related symptoms in outpatients with invasive i cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study, Abst # 9619) Michael J. Fisch,

More information

PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables

PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables PharmaSUG 2012 - Paper IB09 PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables Sneha Sarmukadam, Statistical Programmer, PharmaNet/i3, Pune, India Sandeep

More information

ADVANCED VBA FOR PROJECT FINANCE Near Future Ltd. Registration no

ADVANCED VBA FOR PROJECT FINANCE Near Future Ltd. Registration no ADVANCED VBA FOR PROJECT FINANCE f i n a n c i a l f o r e c a s t i n G 2017 Near Future Ltd. Registration no. 10321258 www.nearfuturefinance.com info@nearfuturefinance.com COURSE OVERVIEW This course

More information

Investigating the performance of a CAD x scheme for mammography in specific BIRADS categories

Investigating the performance of a CAD x scheme for mammography in specific BIRADS categories Investigating the performance of a CAD x scheme for mammography in specific BIRADS categories Andreadis I., Nikita K. Department of Electrical and Computer Engineering National Technical University of

More information

One-Way Independent ANOVA

One-Way Independent ANOVA One-Way Independent ANOVA Analysis of Variance (ANOVA) is a common and robust statistical test that you can use to compare the mean scores collected from different conditions or groups in an experiment.

More information

Palliative Care: Expanding the Role Throughout the Patient s Journey. Dr. Robert Sauls Regional Lead for Palliative Care

Palliative Care: Expanding the Role Throughout the Patient s Journey. Dr. Robert Sauls Regional Lead for Palliative Care Palliative Care: Expanding the Role Throughout the Patient s Journey Dr. Robert Sauls Regional Lead for Palliative Care 1 Faculty/Presenter Disclosure Faculty: Dr. Robert Sauls MD, with the Mississauga

More information

Josh is JB s brother and caregiver.

Josh is JB s brother and caregiver. PUT GBM ON PAUSE PUT LIFE ON PLAY Josh is JB s brother and caregiver. JB is an Optune user. OPTUNE + TMZ HAS BEEN PROVEN TO PROVIDE LONG-TERM QUALITY SURVIVAL TO PATIENTS WITH NEWLY DIAGNOSED GBM1,2,*

More information

Quality of life across chemotherapy lines in patients with advanced colorectal cancer: a prospective single-center observational study

Quality of life across chemotherapy lines in patients with advanced colorectal cancer: a prospective single-center observational study Quality of life across chemotherapy lines in patients with advanced colorectal cancer: a prospective single-center observational study Beate Mayrbäurl, Johannes M. Giesinger, Sonja Burgstaller, Gudrun

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Improving Informed Consent to Clinical Research. Charles W. Lidz Ph.D.

Improving Informed Consent to Clinical Research. Charles W. Lidz Ph.D. Improving Informed Consent to Clinical Research Charles W. Lidz Ph.D. Housekeeping Items Please note that this broadcast is being recorded and will be available soon for viewing on SPARC s website. Please

More information

INTERMEZZO ONCOQUEST: A TOUCH-SCREEN COMPUTER ASSISTED SYSTEM TO MONITOR HEALTH RELATED QUALITY OF LIFE VIA PATIENT REPORTED OUTCOME MEASURES

INTERMEZZO ONCOQUEST: A TOUCH-SCREEN COMPUTER ASSISTED SYSTEM TO MONITOR HEALTH RELATED QUALITY OF LIFE VIA PATIENT REPORTED OUTCOME MEASURES 24 INTERMEZZO ONCOQUEST INTERMEZZO ONCOQUEST: A TOUCH-SCREEN COMPUTER ASSISTED SYSTEM TO MONITOR HEALTH RELATED QUALITY OF LIFE VIA PATIENT REPORTED OUTCOME MEASURES 26 INTERMEZZO In 2006, the Department

More information

An Introduction to Modern Econometrics Using Stata

An Introduction to Modern Econometrics Using Stata An Introduction to Modern Econometrics Using Stata CHRISTOPHER F. BAUM Department of Economics Boston College A Stata Press Publication StataCorp LP College Station, Texas Contents Illustrations Preface

More information

1. Introduction This updated guidance sets out the preferred way for scoring and presenting the UW-QOL.

1. Introduction This updated guidance sets out the preferred way for scoring and presenting the UW-QOL. University of Washington Quality of Life Questionnaire (UW-QOL v4 and v4.1) Guidance for scoring and presentation Derek Lowe & Simon N Rogers (Updated 21-1-2018) 1. Introduction This updated guidance sets

More information

STA 3024 Spring 2013 EXAM 3 Test Form Code A UF ID #

STA 3024 Spring 2013 EXAM 3 Test Form Code A UF ID # STA 3024 Spring 2013 Name EXAM 3 Test Form Code A UF ID # Instructions: This exam contains 34 Multiple Choice questions. Each question is worth 3 points, for a total of 102 points (there are TWO bonus

More information

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with

More information

Table of Contents Foreword 9 Stay Informed 9 Introduction to Visual Steps 10 What You Will Need 10 Basic Knowledge 11 How to Use This Book

Table of Contents Foreword 9 Stay Informed 9 Introduction to Visual Steps 10 What You Will Need 10 Basic Knowledge 11 How to Use This Book Table of Contents Foreword... 9 Stay Informed... 9 Introduction to Visual Steps... 10 What You Will Need... 10 Basic Knowledge... 11 How to Use This Book... 11 The Screenshots... 12 The Website and Supplementary

More information

Improvement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis

Improvement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis Advances in Peritoneal Dialysis, Vol. 24, 2008 Matthew J. Novak, 1 Heena Sheth, 2 Filitsa H. Bender, 1 Linda Fried, 1,3 Beth Piraino 1 Improvement in Pittsburgh Symptom Score Index After Initiation of

More information